| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; 2 Molecular Pathology Unit, Brain Tumor Center, Neurosurgical Service and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; 3 Cancer Research UK Genetic Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; 4 Johns Hopkins University School of Medicine, Baltimore, Maryland; and 5 Institute of Cancer Research, Sutton, Surrey, United Kingdom
Requests for reprints: P. Andrew Futreal, Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, United Kingdom. Phone: 44-1223-494857; Fax: 44-1223-494809; E-mail: paf{at}sanger.ac.uk.
Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists of extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although a statistically significant increase in survival has been reported with this regimen, nearly all gliomas recur and become insensitive to further treatment with this class of agents. We sequenced 500 kb of genomic DNA corresponding to the kinase domains of 518 protein kinases in each of nine gliomas. Large numbers of somatic mutations were observed in two gliomas recurrent after alkylating agent treatment. The pattern of mutations in these cases showed strong similarity to that induced by alkylating agents in experimental systems. Further investigation revealed inactivating somatic mutations of the mismatch repair gene MSH6 in each case. We propose that inactivating somatic mutations of MSH6 confer resistance to alkylating agents in gliomas in vivo and concurrently unleash accelerated mutagenesis in resistant clones as a consequence of continued exposure to alkylating agents in the presence of defective mismatch repair. The evidence therefore suggests that when MSH6 is inactivated in gliomas, alkylating agents convert from induction of tumor cell death to promotion of neoplastic progression. These observations highlight the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers. (Cancer Res 2006; 66(8): 3987-91)
This article has been cited by other articles:
|
|
 |
|
  S. Yip, J. Miao, D. P. Cahill, A. J. Iafrate, K. Aldape, C. L. Nutt, and D. N. Louis MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance Clin. Cancer Res., July 15, 2009; 15(14): 4622 - 4629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Frosina DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res., July 1, 2009; 7(7): 989 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al. Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme Science, September 26, 2008; 321(5897): 1807 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Maxwell, S. P. Johnson, R. E. McLendon, D. W. Lister, K. S. Horne, A. Rasheed, J. A. Quinn, F. Ali-Osman, A. H. Friedman, P. L. Modrich, et al. Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma Clin. Cancer Res., August 1, 2008; 14(15): 4859 - 4868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Loriaux, R. L. Levine, J. W. Tyner, S. Frohling, C. Scholl, E. P. Stoffregen, G. Wernig, H. Erickson, C. A. Eide, R. Berger, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia Blood, May 1, 2008; 111(9): 4788 - 4796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Verbeek, T. D. Southgate, D. E. Gilham, and G. P. Margison O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy Br. Med. Bull., March 1, 2008; 85(1): 17 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Scott, T. Homfray, N. L Huxter, S. G Mitton, R. Nash, M. N Potter, D. Lancaster, and N. Rahman Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations J. Med. Genet., July 1, 2007; 44(7): e83 - e83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. K. Mirzoeva, T. Kawaguchi, and R. O. Pieper The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol. Cancer Ther., November 1, 2006; 5(11): 2757 - 2766. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
